Systematic Review and Meta-Analysis of Surgical Treatment for Isolated Local Recurrence of Pancreatic Cancer

被引:12
作者
Serafini, Simone [1 ]
Sperti, Cosimo [1 ]
Friziero, Alberto [1 ]
Brazzale, Alessandra Rosalba [2 ]
Buratin, Alessia [3 ]
Ponzoni, Alberto [4 ]
Moletta, Lucia [1 ]
机构
[1] Univ Padua, Surg Clin 3, Dept Surg Oncol & Gastroenterol, Via Giustiniani 2, I-35128 Padua, Italy
[2] Univ Padua, Dept Stat Sci, Via Cesare Battisti 241, I-35121 Padua, Italy
[3] Univ Padua, Dept Biol, Viale G Colombo 3, I-35131 Padua, Italy
[4] Padua Hosp, Dept Radiol, Via Giustiniani 2, I-35128 Padua, Italy
关键词
isolated local recurrence; pancreatectomy; pancreatic cancer; pancreatic remnant; recurrence; redo surgery; LONG-TERM SURVIVAL; DUCTAL ADENOCARCINOMA; RESECTION;
D O I
10.3390/cancers13061277
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Recurrences after primary resection of pancreatic cancer are generally treated with chemotherapy or best supportive care. Despite some reports of encouraging results after the re-resection of recurrences, the real role of surgery in this setting remains unclear. The aim of our systematic review and meta-analysis was to define the benefit of surgery in the case of isolated local recurrence. The data collected on 431 patients suggest an overall survival benefit of 29 months for patients re-operated compared to patients given medical therapies. In selected patients with recurrent pancreatic cancer, resection is safe and feasible, and may offer a survival advantage. Purpose: To perform a systematic review and meta-analysis on the outcome of surgical treatment for isolated local recurrence of pancreatic cancer. Methods: A systematic review and meta-analysis based on Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines was conducted in PubMed, Scopus, and Web of Science. Results: Six studies concerning 431 patients with recurrent pancreatic cancer met the inclusion criteria and were included in the analysis: 176 underwent redo surgery, and 255 received non-surgical treatments. Overall survival and post-recurrence survival were significantly longer in the re-resected group (ratio of means (ROM) 1.99; 95% confidence interval (CI), 1.54-2.56, I-2 = 75.89%, p = 0.006, and ROM = 2.05; 95% CI, 1.48-2.83, I-2 = 76.39%, p = 0.002, respectively) with a median overall survival benefit of 28.7 months (mean difference (MD) 28.7; 95% CI, 10.3-47.0, I-2 = 89.27%, p < 0.001) and median survival benefit of 15.2 months after re-resection (MD 15.2; 95% CI, 8.6-21.8, I-2 = 58.22%, p = 0.048). Conclusion: Resection of isolated pancreatic cancer recurrences is safe and feasible and may offer a survival benefit. Selection of patients and assessment of time and site of recurrence are mandatory.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 32 条
[1]  
AIOM, 2018, CANC NUMB IT
[2]   Pulmonary Resection for Isolated Pancreatic Adenocarcinoma Metastasis: an Analysis of Outcomes and Survival [J].
Arnaoutakis, George J. ;
Rangachari, Deepa ;
Laheru, Daniel A. ;
Iacobuzio-Donahue, Chris A. ;
Hruban, Ralph H. ;
Herman, Joseph M. ;
Edil, Barish H. ;
Pawlik, Timothy M. ;
Schulick, Richard D. ;
Cameron, John L. ;
Meneshian, Avedis ;
Yang, Stephen C. ;
Wolfgang, Christopher L. .
JOURNAL OF GASTROINTESTINAL SURGERY, 2011, 15 (09) :1611-1617
[3]  
CLARKE M, 2001, PLOS MED, V357, P1728, DOI DOI 10.1016/S0140-6736(00)04934-5
[4]   Genetics and Biology of Pancreatic Ductal Adenocarcinoma [J].
Dunne, Richard F. ;
Hezel, Aram F. .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2015, 29 (04) :595-+
[5]  
DUVAL SJ, 2005, JNCI-J NATL CANCER I, P127
[6]   Bias in meta-analysis detected by a simple, graphical test [J].
Egger, M ;
Smith, GD ;
Schneider, M ;
Minder, C .
BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7109) :629-634
[7]   Pancreatic ductal adenocarcinoma: Long-term survival does not equal cure [J].
Ferrone, Cristina R. ;
Pieretti-Vanmarcke, Rafael ;
Bloom, Jordan P. ;
Zheng, Hui ;
Szymonifka, Jackye ;
Wargo, Jennifer A. ;
Thayer, Sarah P. ;
Lauwers, Gregory Y. ;
Deshpande, Vikram ;
Mino-Kenudson, Mari ;
Fernandez-del Castillo, Carlos ;
Lillemoe, Keith D. ;
Warshaw, Andrew L. .
SURGERY, 2012, 152 (03) :S43-S49
[8]  
GBOLAHAN OB, 2019, EJSO-EUR J SURG ONC, V19, P1, DOI DOI 10.1186/S12885-019-5630-4
[9]  
HACKERT T, 2017, CANCERS, V43, P358, DOI DOI 10.1016/J.EJSO.2016.10.023
[10]  
HASHIMOTO D, 2013, PUBLICATION BIAS MET, V44, P1313, DOI DOI 10.1007/S00595-013-0708-0